Skip to main content

Oncology Advances

Featured Content |Content Library

Updated Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Clinical Trials Video

Updated Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Clinical Trials

Sara Tolaney, MD, MPH discusses updated standardized definitions for efficacy endpoints in adjuvant breast cancer clinical trials: STEEP Version 2.0.

Dana-Farber Cancer Institute Establishes the David Liposarcoma Research Initiative News

Dana-Farber Cancer Institute Establishes the David Liposarcoma Research Initiative

Dana-Farber Cancer Institute announced that The Rossy Foundation has committed $10 million to establish the David Liposarcoma Research Initiative.

Study Pairs Two Forms of Immunotherapy in Patients with Advanced Kidney Cancer News

Study Pairs Two Forms of Immunotherapy in Patients with Advanced Kidney Cancer

T cells revved up to attack tumors are turned into an army of loiterers. Cells keenly attuned to signals of infection or disease fail to pick up the faint notes of cancer. A clinical trial led by Dana-Farber researchers is addressing both ...

Phenotype, Specificity and Avidity of Antitumour CD8+ T Cells in Melanoma Video

Phenotype, Specificity and Avidity of Antitumour CD8+ T Cells in Melanoma

Dana-Farber's Giacomo Oliveira, PhD describes a study he led with Cathy Wu, MD, that appeared in Nature.

Antibiotic Novobiocin Found to Kill Tumor Cells with DNA-Repair Glitch News

Antibiotic Novobiocin Found to Kill Tumor Cells with DNA-Repair Glitch

An antibiotic developed in the 1950s and largely supplanted by newer drugs, effectively targets and kills cancer cells with a common genetic defect, laboratory research by Dana-Farber Cancer Institute scientists shows.

Cancer Screenings Rebounded in Late 2020 After COVID-related Decline, but Racial and Economic Disparities Remain for Some Tests News

Cancer Screenings Rebounded in Late 2020 After COVID-related Decline, but Racial and Economic Disparities Remain for Some Tests

The numbers of cancer screening tests rebounded sharply in the last quarter of 2020, following a dramatic decline in the first months of the COVID-19 pandemic, at one large hospital system in the Northeastern United States. These findings ...